Latest Breaking News On - Following standard - Page 1 : comparemela.com

Laekna Therapeutics will present two clinical study results in ESMO 2021 News provided by Share this article Share this article SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ Laekna Therapeutics, an emerging innovative pharma company based in China s Zhangjiang Pharma Valley and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced today that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology (ESMO) Congress 2021. ePoster Presentation Number: 597P This ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC).  LAE001 is the first CYP17/CYP11B2 dual inhibitor globally. It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen

United statesNew jerseyCleo zhangLeah liuAlberto bessudo encinitasEuropean society for medical oncologyEuropean societyMedical oncologyPhasei dose escalation studyPrednisone plus afuresertibMetastatic castration resistant prostate cancerFollowing standardAlberto bessudoCentral european summertimeLaekna therapeuticsஒன்றுபட்டது மாநிலங்களில்